Prosecution Insights
Last updated: April 19, 2026

Knowles Intellectual Property Strategies, LLC

29 pending office actions • 15 clients

Portfolio Summary

29
Total Pending OAs
3
Final Rejections
26
Non-Final OAs

Client Portfolio (15 clients)

Client (Assignee)Pending OAs
Ohio State Innovation Foundation 6
Atea Pharmaceuticals, Inc. 5
Pharmacosmos Holding A/S 3
Avilar Therapeutics, Inc. 2
Topikos Scientific, Inc. 2
Fennec Pharmaceuticals Inc. 2
Accure Therapeutics, S.L. 1
Mayo Foundation for Medical Education and Research 1
Oculis Operations Sàrl 1
The United States Department of Veterans Affairs 1
Mayo Foundation for Medical Education and Research 1
Hoffmann-La Roche, Inc. 1
The United States Department of Veterans Affairs 1
The President and Fellows of Harvard College 1
Fundació De Recerca Clínic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
19329423 Untitled Ohio State Innovation Foundation COFFA, SERGIO 1658 Non-Final OA
19179878 Untitled Avilar Therapeutics, Inc. GALSTER, SAMUEL LEONARD 1693 Non-Final OA
19350774 Untitled Atea Pharmaceuticals, Inc. LEWIS, PATRICK T 1691 Non-Final OA
19410698 Untitled Topikos Scientific, Inc. VALENROD, YEVGENY 1628 Non-Final OA
19329440 Untitled Ohio State Innovation Foundation REYNOLDS, FRED H 1658 Non-Final OA
19329410 Untitled Ohio State Innovation Foundation HELLMAN, KRISTINA M 1654 Non-Final OA
19401124 Untitled Accure Therapeutics, S.L. ROZOF, TIMOTHY R 1625 Non-Final OA
19329358 CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF Ohio State Innovation Foundation KATAKAM, SUDHAKAR 1658 Non-Final OA Sep 15, 2025
19329427 CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS Ohio State Innovation Foundation COFFA, SERGIO 1658 Non-Final OA Sep 15, 2025
19329417 CELL-PENETRATING PEPTIDE COMPOUNDS Ohio State Innovation Foundation DABKOWSKI, ERINNE R 1654 Non-Final OA Sep 15, 2025
19313605 TOPICAL OCULAR DELIVERY OF CROMAKALIM Mayo Foundation for Medical Education and Research RAMOS LEWIS, JOSMALEN MILAGROS 1621 Non-Final OA Aug 28, 2025
19081912 POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS Avilar Therapeutics, Inc. SIMMONS, CHRIS E 1622 Non-Final OA Mar 17, 2025
18936782 HALIDE-FREE AMMONIUM SILANES Topikos Scientific, Inc. VALENROD, YEVGENY 1628 Non-Final OA Nov 04, 2024
18917928 METHOD OF TREATING DIABETIC MACULAR EDEMA Oculis Operations Sàrl HUANG, GIGI GEORGIANA 1613 Final Rejection Oct 16, 2024
18739149 NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS Atea Pharmaceuticals, Inc. MCINTOSH III, TRAVISS C 1693 Final Rejection Jun 10, 2024
18540608 ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY Atea Pharmaceuticals, Inc. LEWIS, PATRICK T 1691 Non-Final OA Dec 14, 2023
18503027 Anhydrous Sodium Thiosulfate and Formulations Thereof Fennec Pharmaceuticals Inc. GEMBEH, SHIRLEY V 1615 Non-Final OA Nov 06, 2023
18375162 ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF Fennec Pharmaceuticals Inc. KWON, JOHN SEUNGJAI 1615 Non-Final OA Sep 29, 2023
18236836 METHOD FOR REDUCING OTOTOXICITY IN PEDIATRIC PATIENTS RECEIVING PLATINUM-BASED CHEMOTHERAPY The United States Department of Veterans Affairs HOWELL, THEODORE R 1628 Non-Final OA Aug 22, 2023
18231091 TRANSIENT PROTECTION OF NORMAL CELLS DURING CHEMOTHERAPY Pharmacosmos Holding A/S CRAIGO, BAHAR ALAWI 1699 Non-Final OA Aug 07, 2023
18343437 Treatment for Intraocular Pressure Related Disorders Mayo Foundation for Medical Education and Research MOLOYE, TITILAYO 1632 Non-Final OA Jun 28, 2023
18210991 NEW ARYL-PYRIDO-PYRIMIDIN-ONE DERIVATIVES Hoffmann-La Roche, Inc. LEE, CHIHYI NMN 1628 Non-Final OA Jun 16, 2023
18195296 Method for Reducing Ototoxicity in Pediatric Patients Receiving Plantinum-Based Chemotherapy The United States Department of Veterans Affairs HOWELL, THEODORE R 1628 Non-Final OA May 09, 2023
18111316 STEREOSELECTIVE MANUFACTURE OF SELECTED PURINE PHOSPHORAMIDATES Atea Pharmaceuticals, Inc. PIHONAK, SARAH 1627 Non-Final OA Feb 17, 2023
17983098 TREATMENT OF METABOLIC DISORDERS THROUGH THE TARGETING OF A NOVEL CIRCULATING HORMONE COMPLEX The President and Fellows of Harvard College GERIDO, DWAN A 1797 Non-Final OA Nov 08, 2022
17971318 STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES Atea Pharmaceuticals, Inc. WILLIS, DOUGLAS M 1624 Non-Final OA Oct 21, 2022
17890130 HIGHLY ACTIVE ANTI-NEOPLASTIC AND ANTI-PROLIFERATIVE AGENTS Pharmacosmos Holding A/S CORNET, JEAN P 1628 Non-Final OA Aug 17, 2022
17718052 TARGETED TREATMENT OF CANCERS WITH DYSREGULATED FIBROBLAST GROWTH FACTOR RECEPTOR SIGNALING Pharmacosmos Holding A/S BELL, SARA ELIZABETH 1625 Non-Final OA Apr 11, 2022
17622660 COMBINATION THERAPY METHODS, COMPOSITIONS AND KITS Fundació De Recerca Clínic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer D' AMBROSIO, THEA 1654 Final Rejection Dec 23, 2021

Managing Knowles Intellectual Property Strategies, LLC's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month